RxDoctor Payments Data

Esther Morrison, MD

Infectious Disease · Fort Myers, FLNPI 1972629392

Payments from drug & device makers

$3,762in general payments, 2019–2025

Across 154 payments — averaging $24.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$939
  • Viiv Healthcare Company$821
  • Melinta Therapeutics, LLC$370
  • Astellas Pharma US Inc$351
  • Johnson & Johnson$338
  • Gilead$280
  • plus $662 from 12 others

What the payments were for

  • Food & beverage$3,56095%
  • Education$2025%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,762 in reported general payments places this provider in the 70th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$15,833
Medicare patients
64
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala36$158,402
DovatoDolutegravir Sodium/Lamivudine30$101,434
TivicayDolutegravir Sodium35$87,629
TriumeqAbacavir/Dolutegravir/Lamivudi15$60,396
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf12$60,352
DescovyEmtricitabine/Tenofov Alafenam19$43,358
PrezcobixDarunavir/Cobicistat12$28,053
Nafcillin Sodium12$6,257
Vancomycin Hcl41$2,507
Doxycycline Hyclate31$1,093
Sodium Chloride0.9 % Sodium Chloride70$738
CeftriaxoneCeftriaxone Sodium24$691
Cefazolin Sodium13$639
Fluconazole12$538
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim23$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Tivicay, Triumeq$821$249,46080 claims
GileadBiktarvy, Descovy$280$201,76055 claims
Janssen Products, LPSymtuza$99$60,35212 claims
Johnson & JohnsonPrezcobix$338$28,05312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →